ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026)

ArriVent BioPharma has disclosed Net Cash Flow across 4 years of filings, most recently posting $16.6 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $16.6 million, up 167.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.2 million (up 116.3% YoY), and the FY2025 annual result was -$28.8 million, up 62.21% from the prior year.
• Net Cash Flow came in at $16.6 million for Q1 2026 at ArriVent BioPharma, up from -$67.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $167.0 million in Q1 2024 to a low of -$67.1 million in Q4 2025.
• The 4-year median for Net Cash Flow is -$15.8 million (2024), against an average of $7.0 million.
• Across the five-year window, Net Cash Flow soared 494.57% in 2024 and tumbled 317.05% in 2025, its largest moves.
• ArriVent BioPharma's Net Cash Flow stood at -$16.0 million in 2023, then dropped by 0.8% to -$16.1 million in 2024, then sank by 317.05% to -$67.1 million in 2025, then jumped by 124.67% to $16.6 million in 2026.
• The last three Net Cash Flow figures came in at $16.6 million (Q1 2026), -$67.1 million (Q4 2025), and -$93000.0 (Q3 2025), per Business Quant data.